Thomas Keane
Urology · Charleston, SCNPI 1972558708
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 25.8% of the total. Reporting peaked in 2019 at $23,283 and has fallen 99.5% since, to $126 in 2024. Among urology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $916.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$13K
- Myovant Sciences Inc.$12K
- Ferring International Center SA$5K
- Tolmar Pharmaceuticals, Inc.$5K
- Janssen Scientific Affairs, LLC$4K
- Clovis Oncology, Inc.$3K
- plus $11K from 10 others
Across 51 payments — averaging $4488.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$177K
- Ferring International Pharmascience Center US$31K
- Ferring Pharmaceuticals AS$20K
- Pfizer$624
What the payments were for
- Consulting fees$27,48653%
- Speaking & faculty fees$21,71142%
- Travel & lodging$1,2682%
- Food & beverage$1,6833%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 13 | $13,465 |
| Myovant Sciences Inc. | 6 | $11,671 |
| Ferring International Center SA | 2 | $4,975 |
| Tolmar Pharmaceuticals, Inc. | 2 | $4,531 |
| Janssen Scientific Affairs, LLC | 5 | $3,767 |
| Clovis Oncology, Inc. | 8 | $3,281 |
| Ferring Sendirian Berhad | 1 | $2,785 |
| Bayer | 1 | $2,296 |
| Astellas Pharma US Inc | 1 | $2,259 |
| Pfizer | 7 | $1,298 |
| Blue Earth Diagnostics | 3 | $1,201 |
| Boston Scientific | 4 | $328 |
| Urogen Pharma, Inc. | 1 | $141 |
| AstraZeneca | 1 | $132 |
| Astellas Pharma Global Development | 1 | $64 |
| Teleflex LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,212 in reported general payments places this provider in the 95th percentile of 196 urology providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 11 | $247 |
| Finasteride | 18 | $92 |
Paid to pharmacies, not to this prescriber.
Other urology in Charleston
- Sandip PrasadCharleston$177K
- Ian MarshallCharleston$60K
- Stephen SavageCharleston$32K
- Matvey TsivianCharleston$18K
- John BrittonCharleston$15K
- John AdamsCharleston$15K
- Bradley SteeleCharleston$12K
- Alexander RamsayCharleston$10K
- Mark BuchananCharleston$8K
- Daniel FurlongCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.